Should Gilead Be Worried About This New Monthly HIV Medication?

Gilead Sciences (NASDAQ:GILD) has seen quite a bit of competition in the hepatitis C (HCV) space, but now investors in the big biotech also need to start worrying about potential competition for its HIV drugs, a segment that has been growing.